1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
According to the recently published report 'Placenta Growth Factor - Pipeline Review, H2 2020'; Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) pipeline Target constitutes close to 27 molecules.
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Placental growth factor is a protein encoded by the PGF gene. Placental growth factor (PGF) is a member of the VEGF (vascular endothelial growth factor). It plays an important role in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. PGF is also expressed in many other tissues, including the villous trophoblast.
The report 'Placenta Growth Factor - Pipeline Review, H2 2020' outlays comprehensive information on the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 1, 5, 6, 6 and 1 respectively. Report covers products from therapy areas Ophthalmology, Metabolic Disorders and Oncology which include indications Wet (Neovascular/Exudative) Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema, Central Retinal Vein Occlusion, Metastatic Colorectal Cancer, Retinopathy, Age Related Macular Degeneration, Branch Retinal Vein Occlusion, Choroidal Neovascularization, Corneal Neovascularization, Graves' Ophthalmopathy, Medulloblastoma, Myopia, Non-Proliferative Diabetic Retinopathy (NPDR), Optic Neuropathy, Retinal Vein Occlusion, Retinopathy Of Prematurity, Solid Tumor and Uveal Melanoma.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)
- The report reviews Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics and enlists all their major and minor projects
- The report assesses Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Overview
- Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Development
- Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Assessment
- Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Companies Involved in Therapeutics Development
- Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Drug Profiles
- Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Dormant Products
- Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Discontinued Products
- Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development by Stage of Development, H2 2020
- Number of Products under Development by Therapy Areas, H2 2020
- Number of Products under Development by Indication, H2 2020
- Number of Products under Development by Companies, H2 2020
- Products under Development by Companies, H2 2020
- Number of Products by Stage and Mechanism of Actions, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Pipeline by Alteogen Inc, H2 2020
- Pipeline by Amgen Inc, H2 2020
- Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H2 2020
- Pipeline by Cinnagen Co, H2 2020
- Pipeline by Clover Biopharmaceuticals, H2 2020
- Pipeline by Coherus BioSciences Inc, H2 2020
- Pipeline by Formycon AG, H2 2020
- Pipeline by Gene Techno Science Co Ltd, H2 2020
- Pipeline by GlycoNex Inc, H2 2020
- Pipeline by Huons Global Co Ltd, H2 2020
- Pipeline by i2 Pharmaceuticals Inc, H2 2020
- Pipeline by Lupin Ltd, H2 2020
- Pipeline by Luye Pharma Group Ltd, H2 2020
- Dormant Projects, H2 2020
- Discontinued Products, H2 2020
List of Figures
- Number of Products under Development by Stage of Development, H2 2020
- Number of Products under Development by Therapy Areas, H2 2020
- Number of Products under Development by Top 10 Indications, H2 2020
- Number of Products by Stage and Mechanism of Actions, H2 2020
- Number of Products by Routes of Administration, H2 2020
- Number of Products by Stage and Routes of Administration, H2 2020
- Number of Products by Molecule Types, H2 2020
- Number of Products by Stage and Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alteogen Inc
- Amgen Inc
- Chengdu Kanghong Pharmaceuticals Group Co Ltd
- Cinnagen Co
- Clover Biopharmaceuticals
- Coherus BioSciences Inc
- Formycon AG
- Gene Techno Science Co Ltd
- GlycoNex Inc
- Huons Global Co Ltd
- i2 Pharmaceuticals Inc
- Lupin Ltd
- Luye Pharma Group Ltd
- Momenta Pharmaceuticals Inc
- Oncosimis Biotech Pvt Ltd
- Oxurion NV
- Panolos Bioscience
- PharmAbcine Inc
- Prestige BioPharma Pte Ltd
- Regeneron Pharmaceuticals Inc
- Sam Chun Dang Pharm Co Ltd
- Samsung Bioepis Co Ltd
